FDA ALERT: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal Infections
FDA ALERT
The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs’ prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.
The four drugs, known as tumor necrosis factor alpha blockers (TNF-alpha blockers), which suppress the immune system, are approved to treat a variety of conditions which may include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and Crohn’s disease.
~~~
Tags: chronic pain blog, pain blog, arthritis, tumor necrosis factor alpha blocker, TNF alpha blocker, humira, cimzia, enbrel, remicade, invasive fungal infections, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease, TNF
Related Stories
POSTED IN: FDA Announcements
0 opinions for FDA ALERT: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal Infections
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: